Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated MelanomaJames Larkin, Antoni Ribas, Paolo A. Ascierto et al.|New England Journal of Medicine|2014Cited by 2k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialReinhard Dummer, Keith T. Flaherty, Laure A Moutouh-de Parseval et al.|The Lancet Oncology|2018Cited by 1k
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Keith T. Flaherty, Paolo A. Ascierto et al.|The Lancet Oncology|2018Cited by 586
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Keith T. Flaherty, Dirk Schadendorf et al.|The Lancet Oncology|2017Cited by 491
5-Year Outcomes with Cobimetinib plus Vemurafenib in <i>BRAF</i> V600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM StudyPaolo A. Ascierto, Grant A. McArthur, Brigitte Dréno et al.|Clinical Cancer Research|2021Cited by 182